Company Overview - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] - The company is advancing verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin, which is involved in inflammatory responses [2] - Verekitug is currently in separate Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to initiate development for chronic obstructive pulmonary disease [2] Upcoming Events - Rand Sutherland, MD, MPH, the CEO of Upstream Bio, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 p.m. PT [1] - A live webcast of the presentation will be available on the company's website, with a replay posted afterward [1]
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference